Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_assertion type Assertion NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_head.
- NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_assertion description "[Examples of drugs developed as a result of targeting GPCRs mutated in disease include: calcimimetics and calcilytics, therapeutics targeting melanocortin receptors in obesity, interventions that alter GNRHR loss from the cell surface in idiopathic hypogonadotropic hypogonadism and novel drugs that might rescue the P2RY12 receptor congenital bleeding phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_provenance.
- NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_assertion evidence source_evidence_literature NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_provenance.
- NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_assertion SIO_000772 25150870 NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_provenance.
- NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_assertion wasDerivedFrom befree-2016 NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_provenance.
- NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_assertion wasGeneratedBy ECO_0000203 NP1213131.RAtM5mtVPvG9dJ25bO7qFSZ8WllDVUYvXkd8JX44KgrZg130_provenance.